DOCSLIB.ORG

When Will the ACE-Inhibitors Be Declared Obsolete?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
When Will the ACE-Inhibitors Be Declared Obsolete? Journal of Human Hypertension (2000) 14, 79–81 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh COMMENTARY When will the ACE-inhibitors be declared obsolete? WJ Elliott Department of Preventive Medicine, RUSH Medical College of RUSH University at RUSH-Presbyterian-St. Luke’s Medical Center, Chicago, IL, USA Keywords: ACE inhibitors; angiotensin II receptor blockers Although there are currently many effective classes There are essentially two scenarios in which it of antihypertensive medications from which to might be possible to consider the ACE-inhibitors choose a specific agent to treat elevated blood press- obsolete medications, having been ‘put out to pas- ure, the angiotensin-converting enzyme (ACE) ture’ by the angiotensin II receptor blockers. One inhibitors occupy a special place. Besides the fact scenario is based on the current penchant for ‘evi- that these agents were developed in a rather more dence-based medicine’, and the other is primarily ‘rational’ way1 than many other drugs which were based on a more fundamental issue: economics. derived from natural products or synthetic chemi- One of the most pervasive trends in medicine in cals, there are few antihypertensive agents that have the last 20 years has been the growth and wide been as widely studied and whose benefits have acceptance of ‘evidence-based medicine’: the theory now been proven in clinical trials in a broad variety that medicine should adopt those practices and pro- of concomitant medical conditions. ACE-inhibitors cedures which have been shown by clinical trials to have been shown, in trials against placebo, to result in improved outcomes for individuals with improve prognosis in heart failure,2 post-myocardial the disease in question.19 This trend satisfies both infarction,3–7 renal impairment,8–10 Type I diabetic the medical scientists (whose work in clinical trials nephropathy,11 and many other conditions (eg, largely forms the basis for widespread recom- scleroderma12). mendations) and traditional (ie, ‘conservative’) The ACE-inhibitors are now being challenged physicians. Because clinical trials of a new treat- worldwide by another effective way of interfering ment typically require many years for completion, with the vasoconstriction and other untoward phar- ‘older treatments’ usually have a several-year advan- macological properties of angiotensin II: direct tage over ‘newer treatments’, based on the precepts 13 blockade of the AT1 receptor. The angiotensin II of ‘evidence-based medicine’. This situation is very receptor blockers (ARBs) have apparently nearly the well illustrated in the comparison of ACE-inhibitors same efficacy in lowering blood pressure (at least in and ARBs: the ACE-inhibitors have a 10–15 year meta-analysis) as the ACE-inhibitors,14 and very lead in clinical trial data, with many studies show- much lower rates of adverse effects (especially ing (for instance) a major significant survival benefit cough15–18 and angioneurotic oedema). Many phar- among heart failure patients, such that a prominent maceutical companies have begun large marketing editorial about one such trial anointed ACE-inhibi- efforts to persuade physicians and patients to use tors the ‘cornerstone of heart failure therapy’.20 the newer agents first, which has sometimes resulted Although there have been some recent refinements in the following conversation in consulting rooms: to ‘optimal’ therapy for heart failure (which now Healthcare provider: ‘I am going to prescribe these often includes digoxin, a low-dose beta-blocker,21,22 tablets for your high blood pressure. If they cause and spironolactone23), most current research in side-effects, don’t worry; I will give you a somewhat heart failure is being done with the blinded study similar medication that typically doesn’t cause these medication being added to standard-of-care therapy side-effects.’ (which nearly always includes an ACE-inhibitor). In Healthcare consumer: ‘Well, then, why don’t you fact, for many of the ongoing and currently-planned just give me the second medication now, and avoid studies of ARBs in heart failure, it was considered the side-effects all together!’ unethical to ‘deprive’ patients of ACE-inhibitors, and instead give them the newer ARBs; as a result, several of the clinical trials are being conducted Correspondence: Dr William J Elliott, Department of Preventive Medicine, RUSH Medical College of RUSH University at RUSH- with all heart failure patients on an ACE-inhibitor, Presbyterian-St. Luke’s Medical Center, 1700 West Van Buren to which is added either placebo or an ARB. This Street, Suite 470 Chicago, IL 60612, USA situation essentially makes it impossible to obtain ACE-inhibitors replaced by ARBs? WJ Elliott 80 data supporting the use of an ARB alone as an effec- tive treatment for heart failure (or any of the other disease states for which ACE-inhibitors are now so useful). When (and if) current and future research proves that ARBs are at least as effective (if not more effective) than ACE-inhibitors for the prevention of morbidity and mortality, then the suggestion of the patient in the above vignette may be vindicated. Until then, a reasonable rebuttal to the suggestion would be that, ‘We have clear data showing the benefits of the tablets I’m about to give you, in reducing the complications of high blood pressure. If you can take them without experiencing side- Figure 2 Average wholesale prices for the five ARBs that are com- effects, it is likely that they will improve your prog- mercially marketed in the USA. Costs are annual pharmacy costs nosis as they have improved the lot of patients who for the recommended initial starting dose, as reported in the most recent survey of The Medical Letter on Drugs and Therapeutics.24 were given them in clinical trials. If you can’t toler- ate them, obviously we will be forced to try some- thing else less well-proven.’ about the time that the most popular ACE-inhibitors The second argument which can be marshalled by were at the end of their patent lives, and promoted the health care provider in favour of using an ACE- by companies with large profits to lose when the inhibitor rather than an ARB is based on economics. ACE-inhibitor was no longer protected by patent. If Perhaps because ACE-inhibitors have been seen as (and when) the economics of acquiring an ARB are the most homogeneous of the ‘traditional’ antihyper- competitive with the cost of an ACE-inhibitor, there tensive drugs (as compared, for instance, to will be a greater interest among physicians, pharma- diuretics, beta-blockers, and calcium antagonists), cists, and the organizations that employ them, in many authorities see very little difference between allowing the health care consumer to receive these the agents, except for those related to economics. medications primarily. The ACE-inhibitors are an excellent example of ‘lais- In the USA, it is much more typical for the health sez-faire’ economics: as the therapeutic class became care provider to use the economic argument to rebut more crowded, costs for these agents declined (see the suggestion given by the consumer above. There Figure 1). Furthermore, generic captopril has are currently several methods that enterprising become available at an average wholesale price of medical care systems have put into place to enforce approximately US$0.04 per day to several health the primary choice of ACE-inhibitors in this setting. care plans with aggressive pharmacy benefits man- It is common practice for ARBs to be dispensed only agers, which is competitive with other generic anti- if the pharmacist has a record of a previous dispen- hypertensive agents, and approximately 28 times sing of an ACE-inhibitor, typically within the pre- cheaper than the currently-least expensive ARB.24 vious 90 days. To ensure that only patients with Unfortunately, despite perhaps even greater homo- legitimate previous adverse effects with ACE-inhibi- geneity among the ARBs (even compared to ACE- tors (eg, angioedema or persistent dry cough) receive inhibitors), the ARBs have not shown a similar dec- the more expensive drug, many pharmacy benefits rement in average wholesale prices in the USA (see managers require special forms to be completed Figure 2); the recommended starting dose of each is before an ARB can be dispensed. Typically two priced literally within pennies per day of the physicians’ signatures are required on the request others.24 This situation may improve when the sixth for an ARB; some organizations mandate that the ARB is introduced (see Figure 1). There may be little two physicians must have different Federal Tax ID coincidence that the ARBs were introduced just numbers (so that they cannot be business partners or simply sign each others’ forms without forming an independent assessment). These requirements have been put into place to ensure that the less- expensive ACE-inhibitor, with proven benefits in preventing morbidity and mortality in clinical trials, will not be superceded by the ARBs despite fewer side-effects. References 1 Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin con- verting enzyme. Hypertension 1991; 17: 589–592. 2 The SOLVD Investigators. Effect of enalapril on mor- tality and the development of heart failure in asympto- Figure 1 Average wholesale prices for the nine ACE-inhibitors matic patients with reduced left ventricular ejection that are commercially available in the USA. Costs are the annual fractions. N Engl J Med 1992; 327: 685–691. pharmacy costs for the ‘second-step’ dose, as offered in the largest 3 Pfeffer MA et al. Effect of captopril on mortality and retail pharmacy on the Internet.25 morbidity in patients with left ventricular dysfunction Journal of Human Hypertension ACE-inhibitors replaced by ARBs? WJ Elliott 81 after myocardial infarction. Results of the Survival and 13 Bauer JH, Reams GP.
Load more

Recommended publications
  • Effects of Lacidipine, Ramipril and Valsartan on Serum BNP Levels in Acute and Chronic Periods Following Isoproterenol-Induced Myocardial Infarction in Rats
    Original Article Effects of Lacidipine, Ramipril and Valsartan on Serum BNP Levels in Acute and Chronic Periods Following Isoproterenol-Induced Myocardial Infarction in Rats Lasidipin, Ramipril ve Valsartanın Sıçanlarda Isoprotrenol ile Uyarılan Miyokard Infarktüsü Sonrası Akut ve Kronik Periyotta Serum BNP Seviyeleri Üzerine Etkileri Yasin Bayir1, Elif Cadirci2, Halis Suleyman2, Zekai Halici2, Mevlut Sait Keles3 1Ataturk University, Faculty of Pharmacy, Department of Biochemistry, Erzurum, Turkey 2Ataturk University, Faculty of Medicine, Department of Pharmacology, Erzurum, Turkey 3Ataturk University, Faculty of Medicine, Department of Biochemistry, Erzurum, Turkey Correspondence to: Elif Cadirci, Ph.D., Atatürk University, Faculty of Medicine, Department of Pharmacology, 25240, Erzurum, Turkey. Phone: +90.442.2316563, Fax: +90.442.2360968, e-mail: [email protected] Abstract Özet Objective. Myocardial infarction (MI) as a result of cardiovas- Amaç. Miyokard infarktüsü (Mİ) hem gelişmiş hem de cular disease is the principal cause of death in both developed gelişmekte olan ülkelerde kardiyovasküler hastalıklar sonucu and developing countries. Brain natriuretic peptide (BNP) is an oluşan ölümün esas sebebidir. Brain natriuretic peptide (BNP) important marker of cardiac failure. Cardioprotective activities kardiyak hasarın önemli bir göstergesidir. Antihipertansif il- of the antihypertensive drugs lacidipine (LAC), ramipril (RAM) açlar olan lasidipin (LAC), ramipril (RAM) ve valsartanın, izo- and valsartan (VAL), against isoproterenol
    [Show full text]
  • Cardioprotective Role of Zofenopril in Patients with Acute
    Open Heart: first published as 10.1136/openhrt-2014-000220 on 8 September 2015. Downloaded from Coronary artery disease Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double- blind, controlled, prospective studies Claudio Borghi,1 Stefano Omboni,2 Giorgio Reggiardo,3 Stefano Bacchelli,1 Daniela Degli Esposti,1 Ettore Ambrosioni,1 on behalf of the SMILE Working Project To cite: Borghi C, Omboni S, ABSTRACT et al KEY QUESTIONS Reggiardo G, . Background: Early administration of zofenopril Cardioprotective role of following acute myocardial infarction (AMI) proved to zofenopril in patients with What is already known about this subject? be prognostically beneficial in the four individual acute myocardial infarction: a ▸ Use of ACE inhibitors has been shown to be pooled individual data randomised, double-blind, parallel-group, prospective beneficial in preventing major cardiovascular analysis of four randomised, SMILE (Survival of Myocardial Infarction Long-term complications in several large randomised, pro- double-blind, controlled, Evaluation) studies. In the present analysis, we spective early and late intervention trials in prospective studies. Open evaluated the cumulative efficacy of zofenopril by patients with post-acute myocardial infarction Heart 2015;2:e000220. pooling individual data from the four SMILE studies. (AMI). doi:10.1136/openhrt-2014- Methods: 3630 patients with AMI were enrolled and 000220 treated for 6–48 weeks with zofenopril 30–60 mg/day What does this study add? (n=1808), placebo (n=951), lisinopril 5–10 mg/day ▸ Zofenopril is an ACE inhibitor with a proven effi- (n=520) or ramipril 10 mg/day (n=351).
    [Show full text]
  • Cough Induced by Enalapril but Not by Captopril
    Eur Respir J 1989, 2, 289-291 CASE REPORT Cough induced by enalapril but not by captopril H. Puolijoki*, M. Nieminen*, E. Moilanen**, L. Siitonen*, A. Lahdensuo*, P. Reinikainen*, H. Vapaatalo** Cough iruluced by enalapril but 1101 by capropril. H. Puolijoki, M Nieminen, •Tampere University Central Hospital. E. Moilanen, L. Siironen, A. Lahdensuo, P. Reinikainen, If. VapaaJalo. •• Dept of Biomedical Sciences, University of ABSTRACT: We report a 68 yr old woman with hypertension wbo Tampcre. Finland. developed a dry cough on enalaprll but not on captopril therapy. Pul­ monary function te!its, methacholine in halation challenges, total blood Correspondence: H. Puolijoki, Dept of Pulmonary Diseases, Turlcu University Central Hospital, SF- eoslnophiJ counts, and changes In plasma concentrations or prostaglandin 207 40 Preitila, Finland. E2 and tllromboxane 81 did not explain the difference in the adverse reaction between tbese two angiotensin converting enzyme inhibitors. Keywords: ACE inhibitors; captopril; cough; Eur Respir J., 1989, 2, 289- 291. enalapril. Received: March, 1988; accepted after revision August 9, 1988. Angiotensin converting enzyme (ACE) inhibiLors like Case History capropril and ena1april are usually well tolerated. How­ ever, in some patientS they may cause cough as an A 68 yr old non-smoking woman with diabetes, adverse reaction [1]. We report a female patiem who hypertension and compensated heart failure, but with developed a cough on enalapril but not on captopril no respiratory disease or abnormalities on chest X-ray, therapy. We evaluated her lung function, bronchial re­ developed a dry cough but no dyspnoea or posrnasal activity to methacholine, LolaJ blood eosinophi l count as drip during Lreatmem with ena1april (Renitcc®, MSD, E 20 mg·day·1) for hypertension.
    [Show full text]
  • Ace Inhibitors (Angiotensin-Converting Enzyme)
    Medication Instructions Ace Inhibitors (Angiotensin-Converting Enzyme) Generic Brand Benazepril Lotensin Captopril Capoten Enalapril Vasotec Fosinopril Monopril Lisinopril Prinivil, Zestril Do not Moexipril Univasc Quinapril Accupril stop taking Ramipril Altace this medicine Trandolapril Mavik About this Medicine unless told ACE inhibitors are used to treat both high blood pressure (hypertension) and heart failure (HF). They block an enzyme that causes blood vessels to constrict. This to do so allows the blood vessels to relax and dilate. Untreated, high blood pressure can damage to your heart, kidneys and may lead to stroke or heart failure. In HF, using by your an ACE inhibitor can: • Protect your heart from further injury doctor. • Improve your health • Reduce your symptoms • Can prevent heart failure. Generic forms of ACE Inhibitors (benazepril, captopril, enalapril, fosinopril, and lisinopril) may be purchased at a lower price. There are no “generics” for Accupril, Altace Mavik, and of Univasc. Thus their prices are higher. Ask your doctor if one of the generic ACE Inhibitors would work for you. How to Take Use this drug as directed by your doctor. It is best to take these drugs, especially captopril, on an empty stomach one hour before or two hours after meals (unless otherwise instructed by your doctor). Side Effects Along with needed effects, a drug may cause some unwanted effects. Many people will not have any side effects. Most of these side effects are mild and short-lived. Check with your doctor if any of the following side effects occur: • Fever and chills • Hoarseness • Swelling of face, mouth, hands or feet or any trouble in swallowing or breathing • Dizziness or lightheadedness (often a problem with the first dose) Report these side effects if they persist: • Cough – dry or continuing • Loss of taste, diarrhea, nausea, headache or unusual fatigue • Fast or irregular heartbeat, dizziness, lightheadedness • Skin rash Special Guidelines • Sodium in the diet may cause you to retain fluid and increase your blood pressure.
    [Show full text]
  • "Coaprovel, INN-Irbesartan+Hydrochlorothiazide"
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT CoAprovel 150 mg/12.5 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide. Excipient with known effect: Each tablet contains 26.65 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1). 4.2 Posology and method of administration Posology CoAprovel can be taken once daily, with or without food. Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be recommended. When clinically appropriate direct change from monotherapy to the fixed combinations may be considered: . CoAprovel 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone; . CoAprovel 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by CoAprovel 150 mg/12.5 mg. CoAprovel 300 mg/25 mg may be administered in patients insufficiently controlled by CoAprovel 300 mg/12.5 mg. Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended. When necessary, CoAprovel may be administered with another antihypertensive medicinal product (see sections 4.3, 4.4, 4.5 and 5.1).
    [Show full text]
  • “Captopril” [Mesh
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Open Heart PubMed: 1. (“dose comparison” OR “dose” OR “low dose” OR “high dose” OR “dosage*”) 2. (“captopril” [mesh] OR “Benazepril” OR “Enalapril” [mesh] OR “Enalapril” OR “Cilazapril” [mesh] OR “Cilazapril” OR “Delapril” OR “Imidapril” OR “Lisinopril” [mesh] OR “Lisinopril” OR “Moexipril” OR “Perindopril” [mesh] OR “Perindopril” OR “Quinapril” OR “Ramipril” [mesh] “Ramipril” OR “Spirapril” OR “Temocapril” OR “Trandolapril” OR “Zofenopril” OR “Enalaprilat” [mesh] OR “Enalaprilat” OR “Fosinopril” [mesh] OR “Fosinopril” OR “Teprotide” [mesh] OR “Teprotide” OR “Angiotensin-Converting Enzyme Inhibitors” [mesh] OR “Angiotensin-Converting Enzyme Inhibitors” OR “Angiotensin Converting Enzyme Inhibitors” OR “Inhibitors, Kininase II” OR “Kininase II Antagonists” OR “Kininase II Inhibitors” OR “Angiotensin I-Converting Enzyme Inhibitors” OR “Angiotensin I Converting Enzyme Inhibitors” OR “Antagonists, Angiotensin- Converting Enzyme” OR “Antagonists, Angiotensin Converting Enzyme” OR “Antagonists, Kininase II” OR “Inhibitors, ACE” OR “ACE Inhibitors” OR “Inhibitors, Angiotensin-Converting Enzyme” OR “Enzyme Inhibitors, Angiotensin-Converting” OR “Inhibitors, Angiotensin Converting Enzyme” OR “Angiotensin-Converting Enzyme Antagonists” OR “Angiotensin Converting Enzyme Antagonists” OR “Enzyme Antagonists, Angiotensin-Converting”) 3. (“Heart failure” [mesh] OR “heart failure” OR “Cardiac Failure” OR “Heart Decompensation” OR “Decompensation, Heart” OR “Heart Failure, Right-Sided” OR “Heart Failure, Right Sided” OR “Right-Sided Heart Failure” OR “Right Sided Heart Failure” OR “Myocardial Failure” OR “Congestive Heart Failure” OR “Heart Failure, Congestive” OR “Heart Failure, Left-Sided” OR “Heart Failure, Left Sided” OR “Left-Sided Heart Failure” OR “Left Sided Heart Failure” OR “chronic heart failure” OR "chronic heart" OR (CHF)) 4.
    [Show full text]
  • Summary of Product Characteristics 1. Name Of
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ramipril/Amlodipine Glenmark, 5 mg/5 mg, hard capsules Ramipril/Amlodipine Glenmark, 5 mg/10 mg, hard capsules Ramipril/Amlodipine Glenmark, 10 mg/5 mg, hard capsules Ramipril/Amlodipine Glenmark, 10 mg/10 mg, hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ramipril/Amlodipine Glenmark, 5 mg/5 mg, hard capsules: each capsule contains 5 mg ramipril and amlodipine besilate equivalent to 5 mg amlodipine. Ramipril/Amlodipine Glenmark, 5 mg/10 mg, hard capsules: each capsule contains 5 mg ramipril and amlodipine besilate equivalent to 10 mg amlodipine and . Ramipril/Amlodipine Glenmark, 10 mg/5 mg, hard capsules: each capsule contains 10 mg ramipril and amlodipine besilate equivalent to5 mg amlodipine. Ramipril/Amlodipine Glenmark, 10 mg/10 mg, hard capsules: each capsule contains 10 mg ramipril and amlodipine besilate equivalent to 10 mg amlodipine . For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule Ramipril/Amlodipine Glenmark, 5 mg/5 mg, hard capsules: hard gelatin capsules with a length of 19 mm, cap: opaque pink colour, body: opaque white colour. Content of capsules: white or almost white powder. Ramipril/Amlodipine Glenmark, 5 mg/10 mg, hard capsules: hard gelatin capsules with a length of 19 mm, cap: opaque red - brown colour, body: opaque white colour. Content of capsules: white or almost white powder. Ramipril/Amlodipine Glenmark, 10 mg/5 mg, hard capsules: hard gelatin capsules with a length of 19 mm, cap: opaque dark pink colour, body: opaque white colour. Content of capsules: white or almost white powder.
    [Show full text]
  • Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor
    J Am Board Fam Pract: first published as 10.3122/jabfm.10.5.370 on 1 September 1997. Downloaded from BRIEF REPORTS Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor Adriana]. Pavietic, MD Angioedema is an uncommon adverse effect of cyclobenzaprine, her angioedema was initially be­ angiotensin-converting enzyme (ACE) inhib­ lieved to be an allergic reaction to this drug, and itors. Its frequency ranges from 0.1 percent in pa­ it was discontinued. She was also given 125 mg of tients on captopril, lisinopril, and quinapril to 0.5 methylprednisolone intramuscularly. Her an­ percent in patients on benazepril. l Most cases are gioedema did not improve, and she returned to mild and occur within the first week of treat­ the clinic the following day. She was seen by an­ ment. 2-4 Recent reports indicate that late-onset other physician, who discontinued lisinopril, and angioedema might be more prevalent than ini­ her symptoms resolved within 24 hours. Mter her tially thought, and fatal cases have been de­ ACE inhibitor was discontinued, she experienced scribed.5-11 Many physicians are not familiar with more symptoms and an increased frequency of late-onset angioedema associated with ACE in­ palpitations, but she had no change in exercise hibitors, and a delayed diagnosis can have poten­ tolerance. A cardiologist was consulted, who pre­ tially serious consequences.5,8-II scribed the angiotensin II receptor antagonist losartan (initially at dosages of 25 mg/d and then Case Report 50 mg/d). The patient was advised to report any A 57-year-old African-American woman with symptoms or signs of angioedema immediately copyright.
    [Show full text]
  • THE DOSE an Estimation of Equivalent Doses Between Arbs and Aceis
    THE DOSE An estimation of equivalent doses between ARBs and ACEIs ARBs still currently available as of Jan 26, 2020: Twynsta (telmisartan/amlodipine): 40/5mg. 40/10mg, 80/5mg, 80mg/ 10mg Note: ~$0.73/tablet (ODB covered) Candesartan/Hydrochlorothiazide:16mg/12.5mg, 32mg/12.5mg, 32mg/25mg Irbesartan/Hydrochlorothiazide: 150/12.5mg, 300/12.5mg, 300/25mg Olmesartan/Hydrochlorothiaizde: 20/12.5mg, 40/12.5mg Valsartan/Hydrochlorothiazide: 80/12.5mg, 160/12.5mg, 160/25mg, 320/12.5mg, 320/25mg Note: Availability changes daily. Some pharmacies are able to get candesartan (4mg, 8mg, and 32mg) and irbesartan (300mg). Considerations Patients renal function and hepatic function should be taken into consideration Patients should have blood pressure, lytes and SCr checked with rotation from ARB to ACEI as clinically indicated in 1-4 weeks ACEIs can cause a dry cough in 5-35% of patients and carry a risk of angioedema (0.1-0.2%) Comparable dosages between ACEIs and ARBs- Summary of trials Lisinopril 20mg Enalapril 20mg Perindopril 4mg Ramipril 10mg Candesartan 16mg 8mg 16mg Irbesartan 150mg Telmisartan 80mg 40-80mg 40mg ~80mg Valsartan 160mg 80mg Note: There are variations for approximate equivalent dosages between ACEIs and ARBs in clinical trials. Approximate equivalent doses of ACEI for blood pressure lowering Drug Approximate Initial Daily Dose Usual Daily Maintenance Dose Maximum Daily Duration of Dose Dose Action Equivalence Between ACEIs Cilazapril 2.5mg 2.5-5mg 2.5-5mg dailya 10mg 12-24 hr Enalapril maleate 5mg 2.5-5mg 10-40mg daily (or divided bid)a 40mg 12-24 hr Fosinopril 10mg 10mg 10-40mg daily (or divided bid)a 40mg 24hr Lisinopril 10mg 2.5-10mg 10-40mg daily 80mg 24hr Perindopril 2mg 2-4mg 4-8mg daily 8mg 24hr Quinapril 10mg 5-10mg 10-20mg dailya 40mg 24hr Ramipril 2.5mg 1.25mg-2.5mg 2.5-10mg daily (or divided bid)a 20mg ~24hr a: Some patients may experience a diminished antihypertensive effect toward the end of a 24-hour dosing interval.
    [Show full text]
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
    Angiotensin-Converting Enzyme (ACE) Inhibitors Summary Blood pressure reduction is similar for the ACE inhibitors class, with no clinically meaningful differences between agents. Side effects are infrequent with ACE inhibitors, and are usually mild in severity; the most commonly occurring include cough and hypotension. Captopril and lisinopril do not require hepatic conversion to active metabolites and may be preferred in patients with severe hepatic impairment. Captopril differs from other oral ACE inhibitors in its rapid onset and shorter duration of action, which requires it to be given 2-3 times per day; enalaprilat, an injectable ACE inhibitor also has a rapid onset and shorter duration of action. Pharmacology Angiotensin Converting Enzyme Inhibitors (ACE inhibitors) block the conversion of angiotensin I to angiotensin II through competitive inhibition of the angiotensin converting enzyme. Angiotensin is formed via the renin-angiotensin-aldosterone system (RAAS), an enzymatic cascade that leads to the proteolytic cleavage of angiotensin I by ACEs to angiotensin II. RAAS impacts cardiovascular, renal and adrenal functions via the regulation of systemic blood pressure and electrolyte and fluid balance. Reduction in plasma levels of angiotensin II, a potent vasoconstrictor and negative feedback mediator for renin activity, by ACE inhibitors leads to increased plasma renin activity and decreased blood pressure, vasopressin secretion, sympathetic activation and cell growth. Decreases in plasma angiotensin II levels also results in a reduction in aldosterone secretion, with a subsequent decrease in sodium and water retention.[51035][51036][50907][51037][24005] ACE is found in both the plasma and tissue, but the concentration appears to be greater in tissue (primarily vascular endothelial cells, but also present in other organs including the heart).
    [Show full text]
  • Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin
    DOI: 10.7860/JCDR/2018/31983.11754 Original Article Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Pharmacology Section Receptor Blockers-A Pilot Study S BHUVANESHWARI1, PRAKASH VEL SANKHYA SAROJ2, D VIJAYA3, M SABARI SOWMYA4, R SENTHIL KUMAR5 ABSTRACT Results: Among all, 48% (24 out of 50) of the study population Introduction: Hyponatremia, serum sodium <135 mmol/L, can administered with ACEI and ARB developed hyponatremia. result in neurological manifestation in acute cases, may lead Predisposition to develop hyponatremia was high in males to seizures and coma. Angiotensin Converting Enzyme Inhibitor compared to females. Incidence of hyponatremia was 62.5% (10 (ACEI) and Angiotensin II Receptor Blockers (ARB) are drugs out of 16) in the age group of 56-75 years. Though, incidence of that have been commonly prescribed for the treatment of hyponatremia was 54.5% (18 out of 33) in ACEI group compared hypertension and cardiac diseases. It has become important to 35.2% (6 out of 17) in ARB group, but it was not statistically to evaluate and investigate the incidence of hyponatremia on significant. The study also revealed that metosartan had a higher consumption of these drugs. association with hyponatremia compared to other drugs. Aim: To determine the susceptibility of patients on ACEI and Conclusion: Hyponatremia was induced in nearly 50% of ARB to hyponatremia and to ascertain the drug producing patients taking ACEI and ARB. The incidence of hyponatremia notable hyponatremia among ACEI and ARB. among patients on these two drugs did not show statistical variation. Metosartan showed a higher incidence of Materials and Methods: The study was conducted in a tertiary hyponatremia compared to enalapril, ramipril, captopril, care hospital.
    [Show full text]
  • ACE Inhibitors
    ACE Inhibitors This sheet talks about exposure to ACE inhibitors in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is an ACE inhibitor? Angiotensin-converting-enzyme (ACE) inhibitor is the name used to describe a group of medications used to treat high blood pressure. They have also been used for treating problems with the heart and kidneys. ACE inhibitors are sold under many names, such as: benazepril (Lotensin®), captopril (Capoten®), cilazapril (Inhibace®), enalapril (Vasotec ®, Renitec®), fosinopril, imidapril (Tanatril®), lisinopril (Listril®, Lopril®, Novatec®, Prinivil®, Zestril®), moexipril (Univasc®), perindopril (Aceon®), quinapril (Accupril®), ramipril (Altace®, Prilace®, Ramace®, Ramiwin®, Triatec®, Tritace®), trandolapril (Gopten®, Mavik®, Odrik®) and zofenopril. I take an ACE inhibitor. Can it make it harder for me to get pregnant? Studies have not been done to see if ACE inhibitors could make it harder to get pregnant. I just found out I am pregnant. Should I stop taking my ACE inhibitor? Talk with your healthcare providers before making any changes to how you take your medication(s). They will work with you to determine the most appropriate way to treat your blood pressure. It is important to maintain a healthy blood pressure. Can high blood pressure during my pregnancy cause problems? Uncontrolled high blood pressure that starts before pregnancy or before the 20th week of pregnancy can cause slow growth, low birth weight, or preterm delivery (birth before 37 weeks of pregnancy). Some people develop elevated blood pressure after the 20th week of pregnancy (known as preeclampsia). Treatment depends on how high the blood pressure is and other factors.
    [Show full text]